Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Chiron presents new melanocortin MC4 agonists for obesity and type 2 diabetes

Jan. 14, 2004

GSK claims 1,2-diazepane-based inhibitors of cathepsin K and other proteases

Jan. 14, 2004

Approvable letter for Fortical

Jan. 13, 2004

Nutrition 21 seeks approval of chromium picolinate health benefit claims

Jan. 13, 2004

PPD amends dapoxetine license

Jan. 13, 2004

Effective local bone formation and fracture healing by CP-533536

Jan. 13, 2004

Lipid-lowering effects of lovastatin and a diet containing cholesterol-lowering foods

Jan. 12, 2004

Biopure and the FDA discuss complete response letter for Hemopure BLA

Jan. 12, 2004

Symlin marketing application withdrawn in Switzerland

Jan. 12, 2004

New SGLT2 inhibitor for use in type 2 diabetes covered by BMS patent

Jan. 12, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...